BBI Bbi Hldgs

RNS Number:7500X
BBI Holdings PLC
05 June 2007

                                BBI Holdings plc

                                 Trading Update

BBI Holdings Plc ("BBI"), the AIM listed developer and manufacturer of rapid
result diagnostic tests and enzymes for the diagnostic industry, announces a
trading update for the year ended 31 March 2007.

After a year of significant corporate activity it is pleasing to report that the
core business has demonstrated significant growth in sales and profits. The
opportunities driven by market growth and the new acquisitions provide the basis
for sustained growth for the business in the coming years.

The business continues to develop its manufacturing business and I am pleased to
announce that  the trading results for the year ended 31 March 2007 are in line
with market expectations with Turnover showing an overall increase for the year
of 56%, of which acquisitions contributed 27% and organic growth 29%.

Commenting, Julian Baines said, "As well as achieving results for the year in
line with expectations, which has helped demonstrate the growth prospects for
BBI, I am pleased to announce the signature of an additional manufacturing
contract with a North American company that will further cement the growth in
the current year. We are also in the early stages of the integration of
Theratase into the Group and whilst it is clear initial infrastructural
investment is required I am confident that this, over time, will yield further
growth in this business in addition to the current growth of the BBI business."

The preliminary results for the year ended 31 March 2007 will be announced on 30
July 2007.

Contacts:

For further information please contact:

BBI Holdings plc                          Parkgreen Communications Ltd
Julian Baines, Managing Director          Paul McManus
Tel: 029 2074 7232                        Tel: 020 7479 7933
                                          Mob: 07980 541 893
www.bbigold.com                           Email: paul.mcmanus@parkgreenmedia.com


About BBI Holdings PLC (AIM: BBI):

BBI is a leading supplier of products and services to the global diagnostic and
healthcare industries. BBI floated on AIM on 28 April 2004 at 47p.

BBI operates in three core areas:

1. BBInternational (diagnostics)

Incorporating:
         British Biocell, Cardiff, UK
         BBI Dundee (formerly Alchemy Laboratories), Dundee, UK
         BBI Research, Madison, Wisconsin, USA
         Qnostics, Glasgow, UK

BBI manufactures superior quality gold reagents which are used to bind with
specific antibodies or antigens, which are used in diagnostic tests to provide a
positive or negative visual signal. BBI also provides contract product
development services for leading diagnostic companies using its expertise to
develop rapid result diagnostic tests. BBI also manufactures rapid result
diagnostic tests in the UK and the US. Rapid test manufacture involves placing
conjugate onto a pad or strip and enclosing this within a preformed plastic
package 'housing' designed to the customer's specifications.  BBI's Qnostics
division supplies molecular quality control reagents to the global market place.

www.bbigold.com

2. BBI Enzymes

Incorporating:
         Biozyme, Blaenavon, UK
         Seravac, Cape Town, S Africa.

Theratase was acquired by BBI in May 2007 to form BBI's enzyme division. Biozyme
and Seravac are leading manufacturers and suppliers of high quality specialist
natural enzymes to the medical diagnostics industry. Enzymes are proteins which
drive complex reactions that occur in all living organisms. Their high
specificity and dramatic catalytic activity has been exploited within the
diagnostic industry.

www.theratase.com

3. BBI Healthcare (diabetes)

Brands:
         GlucoGel
         SensoCard Plus
         GlucoTabs

In April 2004 BBI acquired Hypostop (now renamed GlucoGel in the UK). GlucoGel
is an easy to use dextrose gel which is included in the National Institute for
Clinical Excellence's (NICE)  treatment guideline for hypoglycaemia. BBI
Healthcare was founded in April 2006 to manage the sales and marketing of
GlucoGel, and build a diabetes care product portfolio. In July 2006 BBI acquired
the UK's only talking blood glucose meter for the visually impaired called
SensoCard Plus. The acquisition gives BBI exclusive distribution rights for
within the UK, US, Canada and India.



www.bbihealthcare.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

TSTFIMFTMMAMBTR

Bbi Holdings (LSE:BBI)
Historical Stock Chart
From Jun 2024 to Jul 2024

Bbi Holdings (LSE:BBI)
Historical Stock Chart
From Jul 2023 to Jul 2024